Coherus Biosciences (CHRS)
NASDAQ:CHRS
CHRS Stock Chart & Stats
$1.71
-$0.05(-3.18%)
At close: 4:00 PM EST
$1.71
-$0.05(-3.18%)
Day’s Range― - ―
52-Week Range$0.71 - $2.62
Previous CloseN/A
Volume565.36K
Average Volume (3M)1.25M
Market Cap
$251.82M
Enterprise Value$151.77M
Total Cash (Recent Filing)$172.13M
Total Debt (Recent Filing)$40.34M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Apr 30, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding149,889,910
10 Day Avg. Volume672,255
30 Day Avg. Volume1,252,938
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.80
Price to Sales (P/S)4.05
P/FCF Ratio-1.23
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue3.60
Enterprise Value/Gross Profit5.35
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$7.00Price Target Upside309.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.92
Revenue Forecast (FY)$88.25M
Bulls Say, Bears Say
Bulls Say
Antibody Assets For Combination TherapyGlobal rights to two antibodies designed to overcome immune resistance offer potential to enhance LOQTORZI efficacy in combinations, expanding therapeutic reach and market opportunity.
Clinical Benefit Of LOQTORZILOQTORZI shows a durable survival benefit versus chemotherapy in nasopharyngeal carcinoma, underpinning the drug's strong commercial potential and serving as the company's oncology foundation.
Partnerships And Collaboration ValidationA supply agreement with a major pharmaceutical partner and Johnson & Johnson's interest in tagmokitug validate external demand and create a pathway for licensing or cost‑sharing collaborations across additional tumor types.
Bears Say
Profitability And Financing RiskA sizable net loss from continuing operations increases pressure on profitability and raises the likelihood of needing additional financing to sustain operations.
Regulatory And Clinical UncertaintyRegulatory hurdles and the novel nature of CCR8 targeting create meaningful clinical and approval uncertainty that could prevent key products from reaching the market.
Sales Performance And Commercial UptakeLOQTORZI sales falling short of analyst expectations and underpenetration in community oncology settings limit near‑term revenue visibility and slow commercial adoption.
Coherus Biosciences News
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $0.71 and its highest was $2.62 in the past 12 months.
What is Coherus Biosciences’s market cap?
Coherus Biosciences’s market cap is $251.82M.
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is Apr 30, 2026 which is in 16 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on Mar 09, 2026. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.355 by -$0.035.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -0.26.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 149,889,910 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.355. Following the earnings report the stock price went up 1.036%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Currently, no hedge funds are holding shares in CHRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coherus Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (309.36% Upside)
$7.00 (309.36% Upside)
Blogger Sentiment
Bullish
CHRS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 231.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.41%
12-Months-Change
Fundamentals
Return on Equity
789.35%
Trailing 12-Months
Asset Growth
-41.57%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
CHRS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive outlook: the company has materially improved its balance sheet (>$250M divestiture proceeds and >90% debt reduction), demonstrated strong commercial momentum with LOQTORZI (113% y/y revenue growth) and compelling survival data, secured a strategic J&J collaboration, and expects multiple clinical readouts beginning mid-2026. Offsetting items include increased R&D spending (~49% Q4 y/y), remaining legacy liabilities and channel variability, and the multi-year path to achieve commercial scale (target $175M peak in 2028 and quarterly break-even thresholds). Overall, the positive developments (de-risked balance sheet, accelerating revenues, strategic partnerships, and promising clinical signals) outweigh the challenges reported.View all CHRS earnings summariesCHRS Stock 12 Month Forecast
Average Price Target
$7.00
▲(309.36% Upside)
Technical Analysis
Ownership Overview
1.14% Insiders
11.63% Mutual Funds
9.45% Other Institutional Investors
70.18% Public Companies and
Individual Investors